92 related articles for article (PubMed ID: 1395838)
1. Elimination of immune tolerance to hepatitis virus in an animal model.
Wen YM; Zhang W; Xu YY; Luo YF; Li PY
Chin Med J (Engl); 1992 Mar; 105(3):199-203. PubMed ID: 1395838
[TBL] [Abstract][Full Text] [Related]
2. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
4. Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning.
Chassot S; Lambert V; Kay A; Godinot C; Trepo C; Cova L
Virology; 1994 Apr; 200(1):72-8. PubMed ID: 7510440
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
6. Development and application of the serological assay for humoral immune response against duck hepatitis B virus.
Tang N; Huang A; Guo S; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2001 Feb; 9(1):13-5. PubMed ID: 11242126
[TBL] [Abstract][Full Text] [Related]
7. Identification of T-cell epitopes associated with immunity within the surface protein of duck hepatitis B virus.
Welschinger R; Cossart Y; Pouliopoulos J; Dixon R; Vickery K
J Viral Hepat; 2006 Aug; 13(8):515-22. PubMed ID: 16901281
[TBL] [Abstract][Full Text] [Related]
8. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
9. Recombinant vaccinia virus expressing Pre-S/S protein of duck hepatitis B virus and its preliminary use for treatment of persistent infection.
Ma ZM; Kong YY; Wang Y; Wen YM
Acta Virol; 1996; 40(5-6):311-4. PubMed ID: 9171461
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of specific immune responses to duck hepatitis B virus in infected, immune, and uninfected ducks].
Tang N; Huang A; Guo S; Qi Z; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):166-8. PubMed ID: 11412394
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
12. Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks.
Cheung RC; Trujillo DE; Robinson WS; Greenberg HB; Marion PL
Virology; 1990 Jun; 176(2):546-52. PubMed ID: 1693247
[TBL] [Abstract][Full Text] [Related]
13. Fine mapping of neutralization epitopes on duck hepatitis B virus (DHBV) pre-S protein using monoclonal antibodies and overlapping peptides.
Chassot S; Lambert V; Kay A; Godinot C; Roux B; Trepo C; Cova L
Virology; 1993 Jan; 192(1):217-23. PubMed ID: 7685963
[TBL] [Abstract][Full Text] [Related]
14. Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection.
Wen YM; Xiong SD; Zhang W
J Gen Virol; 1994 Feb; 75 ( Pt 2)():335-9. PubMed ID: 8113755
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
16. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.
Khawaja G; Buronfosse T; Jamard C; Abdul F; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans CF; Hartmann D; Cova L
Virology; 2012 Nov; 433(1):192-202. PubMed ID: 22921316
[TBL] [Abstract][Full Text] [Related]
17. [Antisense oligodeoxynucleotide targeted at the pre-s region of DHBV could inhibit virus replication in vivo].
He L; Wu X; Chen C
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Mar; 12(1):1-4. PubMed ID: 12515159
[TBL] [Abstract][Full Text] [Related]
18. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks.
Cova L; Wild CP; Mehrotra R; Turusov V; Shirai T; Lambert V; Jacquet C; Tomatis L; Trépo C; Montesano R
Cancer Res; 1990 Apr; 50(7):2156-63. PubMed ID: 2107970
[TBL] [Abstract][Full Text] [Related]
19. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
[TBL] [Abstract][Full Text] [Related]
20. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.
Khawaja G; Buronfosse T; Jamard C; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans C; Hartmann D; Cova L
Virology; 2012 Mar; 425(1):61-9. PubMed ID: 22284894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
